AVX901

AXP000214.1 · Cancer vaccine

Platform
alphavirus (VEE) virus-like replicon particles
Targets
ERBB2
Originator
AlphaVax
Sponsor
Duke University

Names

NameTypeSource
AVX901preferred name, codecurator, ncit
HER2 ECDTM VRPsynonymncit
VRP-HER2synonymncit

Virus

Role
Vaccine vector
Family
Togaviridae
Virus
Venezuelan equine encephalitis virus (NCBI Taxonomy 11036)
Strain
VEE replicon, packaged as virus-like replicon particles
Replication
non replicating
Modifications
propagation-defective single-cycle replicon with three of seven viral genes replaced by the HER2 insert (extracellular and transmembrane domains, no intracellular domain)
Transgenes
ERBB2 (HER2 ECD+TM)
Route
intramuscular
Source
evidence

Cross-references

NCI Thesaurus
C99903

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03632941A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast CancerTerminatedPhase 22019-03-012023-09-038Breast Cancer; HER2+ Breast Cancer
NCT01526473A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901CompletedPhase 12012-022016-0322HER2+ Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 32732224Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2020cited by trial NCT03632941
PMID 30635338Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.Clinical cancer research : an official journal of the American Association for Cancer Research2019name in abstract: VRP-HER2

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 33902424Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options.Endocrine, metabolic & immune disorders drug targets2022name in abstract: AVX901
PMID 29081765Breast Cancer Vaccines: New Insights.Frontiers in endocrinology2017name in abstract: AVX901

Notes

Virus-like replicon particles encoding the HER2 extracellular and transmembrane domains (HER2 ECD+TM); single-cycle alphavirus replicon with three of seven viral genes replaced by the insert. Phase 1 in HER2-overexpressing advanced cancer (NCT01526473). The alphavirus species is not named in the trial description; VEE is taken from the shared AlphaVax VRP platform and the NCIt concept.

How to cite

AVX901 (AXP000214.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000214.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.